High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Karim Belhadj et al.|Blood|2025Cited by 15
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01Arthur Bobin, Xavier Leleu, Salomon Manier et al.|Blood|2023Cited by 0